LQDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Liquidia Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$34.13−0.22 (-0.64%)

Close on Oct 19, 2026

Market cap: $3.46B
P/E (TTM): 24.6
Dividend yield: –

Dividends

Liquidia has not reported a dividend

No dividend per share appears in Liquidia's annual filings since fiscal 2018.

Where these numbers come from

Parsed from the XBRL in Liquidia's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LQDA.

Revenue growth2233.6% · median 43.6%

Operating margin37.4% · median 7.3%

Net margin30.7% · median -11.1%

Company	Revenue	Growth
INSM	$1.14B	+185.8%
KNSA	$754.05M	+56.7%
LQDA	$450.91M	+2233.6%
INVA	$440.00M	+18.8%
MNKD	$393.63M	+30.5%
PHAR	–	–

Company

Next earnings (est.): Nov 2, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 216
Held by institutions: 81.1%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1819576

Advertisement
300 × 250